drugset / Trial / NCT05548543

A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions

NCT05548543 ↗

Phase 1 Completed 40 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HCP2202 and co-administration of each component in fed condition in healthy volunteers.

Timeline

Start
2022-10-17
Primary completion
2022-12-22
Completion
2022-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP2202 Unknown — —
Subject RLD2202 Unknown — —
Subject RLD2203 Unknown — —

Indications

No indication recorded.